Co-Diagnostics price target lowered to $2.50 from $3 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Co-Diagnostics to $2.50 from $3 and keeps a Neutral rating on the shares following the Q4 report. The firm believes the emergency use authorization for Co-Dx PCR Pro could be granted later this year, which would allow the company to start marketing the device and the test to the point-of-care and at-home settings.